The largest database of trusted experimental protocols

Escherichia coli 055 b5 endotoxin

Manufactured by Merck Group
Sourced in China, United States

Escherichia coli 055:B5 endotoxin is a laboratory reagent derived from the bacterial strain Escherichia coli 055:B5. It is a component of the outer membrane of Gram-negative bacteria and is used in research applications to study the biological effects of endotoxins.

Automatically generated - may contain errors

2 protocols using escherichia coli 055 b5 endotoxin

1

Bioactive Compound Extraction and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Standards of gallic acid, rutin, oxymatrine and aucubin were obtained from Sigma-Aldrich (USA). Folin Ciocalteu’s phenol reagent and aluminum chloride (AlCl3) of Sangon (China) were used in the study. All other solvents and chemicals were of analytical grade.
Escherichia coli 055:B5 endotoxin from Sigma-Aldrich and the cytokine immunoassay kits from Shanghai MLBIO Biotechnology Co. Ltd. (China) were used in the study.
+ Open protocol
+ Expand
2

Induced Intrauterine Inflammation in Sheep

Check if the same lab product or an alternative is used in the 5 most similar protocols
In a previous study [29 (link)], we developed an animal model of necrotizing funisitis and chorioamnionitis (severe in utero inflammations of the umbilical cord and fetal membrane, respectively) using the intravenous administration of granulocyte colony-stimulating factor (G-CSF) and the intraamniotic administration of endotoxin in sheep fetuses. In this experiment, intrauterine inflammation was induced according to the following protocol, the same as previously reported.
At 93-97 DG, 48 hours after surgery, ewes with single fetuses were randomly assigned into 2 treatment groups as follows: (1) the endotoxin group (n = 11), in which fetuses received an intraamniotic injection of 5 mg of endotoxin (Escherichia coli 055:B5 endotoxin; Sigma-Aldrich Co., St Louis, MO, USA) solubilized in 2 mL of saline once after 4 days of surgery. In addition, the fetuses were infused with 40 μg of G-CSF (Neutrogin; Chugai Pharmaceuticals Co. Ltd., Tokyo, Japan) solubilized in 2 mL of saline that was administered into the left jugular vein daily for 2 to 6 days after surgery, to increase the number of leukocytes in the fetoplacental circulation [26 , 27 (link), 29 (link)]. (2) The control group (n = 9), in which fetuses received only saline injections into both the jugular vein and the amniotic fluid.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!